S&P 500 Healthcare Sector SEC Filings — October 30, 2026

30-10-2026

Regeneron reported Q3 2026 total revenues of $5,115.8M, up 36.3% YoY from $3,754.3M, driven by collaboration revenue surging 52.4% to $3,000.5M (including Sanofi profit share of $2,574.9M, up 76.9%) and net product sales rising 13.7% to $1,805.3M. Net income jumped 33.5% to $1,948.7M and diluted EPS rose 35.5% to $18.45, however other income, net plunged 67.4% to $246.5M from $755.8M and gross margin pressure showed in cost of goods sold rising 14.5% versus 13.7% product sales growth. Nine-month operating cash flow slipped 3.5% to $3,675.3M despite net income growth, and the company repurchased $2,363.4M of stock while cash and equivalents rose to $3,659.1M.

• · Accounts receivable rose to $7,578.6M from $5,741.1M at year-end 2025, driving a $1,850.5M cash use in nine-month operating activities versus a $549.3M source in 2025.
• · Inventories declined to $2,894.6M from $3,200.8M, a $110.7M cash source versus a $277.4M use in the prior year.
• · Nine-month 2026 net income of $3,972.8M grew only 8.5% versus 24.4% revenue growth, reflecting a $693.0M other income figure versus $1,520.6M in 2025.
• · Acquired in-process R&D expense rose to $250.4M for nine months 2026 from $105.4M, while Q3 2026 IPR&D fell to $21.5M from $83.1M.
• · Capital expenditures increased to $771.0M from $649.7M in the prior-year nine months.
• · Dividends declared of $98.3M in Q3 2026 and $290.3M paid over nine months; quarterly dividends were roughly $0.97 per share.
• · Accumulated other comprehensive income swung to a $197.5M loss from $77.5M income at year-end 2025, driven by $274.6M unrealized losses on debt securities.
• · A new $720.0M finance lease liability was reclassified from long-term to current at September 30, 2026.
• · Total stockholders' equity rose to $33,498.5M from $31,256.9M at December 31, 2025.

30-10-2026

Gilead reported Q3 2026 total revenues of $8,300M, up 6.8% YoY from $7,769M, driven by product sales rising 12.9% to $8,289M, while royalty, contract and other revenues collapsed 97.4% to just $11M from $424M. Q3 net income fell 20.4% YoY to $2,429M and diluted EPS declined to $1.94 from $2.43, while for the nine-month period the company swung to a net loss of $6,045M (EPS -$4.87) from net income of $6,327M, driven by $11,307M in acquired IPR&D expenses and $1,750M in IPR&D impairments versus $485M and $190M respectively a year earlier.

• · Nine-month 2026 operating loss was $4,346M versus operating income of $8,038M in the prior-year period
• · Nine-month 2026 in-process research and development impairments were $1,750M versus $190M in 2025
• · Retained earnings fell to $3,107M from $13,730M at December 31, 2025
• · Intangible assets, net declined to $13,424M from $16,978M at year-end 2025
• · Long-term marketable debt securities dropped to zero from $2,974M at December 31, 2025
• · Q3 2026 share repurchases averaged $139.84 per share versus $113.25 in Q3 2025
• · Quarterly dividend raised to $0.82 per share from $0.79 per share YoY
• · Nine-month 2026 dividends declared totaled $3,095M ($2.46 per share) versus $2,996M ($2.37 per share) in 2025
• · Q3 2026 other (income) expense was a net expense of $130M versus net income of $569M in Q3 2025
• · Cash and cash equivalents decreased to $6,437M from $7,564M at December 31, 2025

30-10-2026

Vanguard Portfolio Management LLC filed a Schedule 13G disclosing beneficial ownership of 3,974,472 shares of IDEXX Laboratories common stock, representing 5.04% of the class as of September 30, 2026. The filing reports sole dispositive power over all 3,974,472 shares but zero sole voting power, with the position held in the ordinary course of business and not for the purpose of influencing control. The stake crosses the 5% threshold, making Vanguard a reportable major shareholder.

• · Filing is a Schedule 13G under Rule 13d-1(b), indicating a passive/institutional investor status
• · Vanguard reports sole dispositive power over 3,974,472 shares but sole voting power of 0
• · The 13G aggregates holdings of Vanguard Portfolio Management LLC plus affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC
• · No other person's interest in the reported securities exceeds 5%
• · Vanguard certifies securities were acquired in the ordinary course of business and not to influence control of IDEXX
• · IDEXX Laboratories is incorporated in Delaware, SIC code 2835 (In Vitro & In Vivo Diagnostic Substances), headquartered in Westbrook, ME

30-10-2026

Thermo Fisher Scientific disclosed in an 8-K that Executive Vice President Michael D. Shafer will retire effective December 31, 2026, with the announcement made October 27, 2026. The filing contains no financial results, guidance, or quantitative performance data, and no successor or interim replacement was named. The filing also lists the company's registered securities, including common stock and 13 series of senior notes traded on the NYSE.

• · Retirement effective date is December 31, 2026, roughly two months after the October 27, 2026 announcement
• · No successor, interim appointment, or compensatory arrangement was disclosed in the filing
• · Filing signed by Thomas B. Shropshire, Senior Vice President and General Counsel, dated October 30, 2026
• · Company incorporated in Delaware, IRS EIN 04-2209186, principal offices at 168 Third Avenue, Waltham, Massachusetts 02451

30-10-2026

AbbVie reported Q3 2026 net revenues of $17.404 billion, up 10.3% reported (10.5% operational), with GAAP diluted EPS of $2.37 and adjusted diluted EPS of $3.82, both up over 100%. Immunology ($9.165B, +16.3%) and Neuroscience ($3.389B, +19.4%) drove growth, while Oncology was nearly flat (+0.8%) and Aesthetics declined 1.4%; Humira fell 31.2% and Imbruvica dropped 26.1%. The company raised 2026 adjusted EPS guidance to $13.95-$13.99 and announced a 5.2% dividend increase for 2027, alongside completing the Apogee Therapeutics acquisition.

• · Adjusted diluted EPS of $3.82 includes an unfavorable $0.11 per share impact from acquired IPR&D and milestones expense
• · 2026 adjusted diluted EPS guidance raised to $13.95-$13.99 from $13.76-$13.96, including $0.69 per share unfavorable IPR&D/milestones impact YTD
• · GAAP SG&A was 23.5% of net revenues vs adjusted 21.2%; GAAP R&D was 14.7% vs adjusted 13.9%
• · Acquired IPR&D and milestones expense was 1.2% of net revenues
• · FDA approved Skyrizi for subcutaneous induction in Crohn's disease and updated TB testing warning/precautions
• · FDA approved Juvmo (tavapadon) as the only selective D1/D5 receptor agonist for Parkinson's disease
• · FDA granted two Breakthrough Therapy Designations for telisotuzumab adizutecan (Temab-A) in colorectal and non-small cell lung cancer
• · Lutikizumab met primary endpoint (HiSCR 75 at Week 16) in Phase 3 INTREPID for hidradenitis suppurativa; regulatory submissions planned H2 2027
• · Qulipta met primary and all eight ranked secondary endpoints in Phase 3 LUNA for menstrual migraine prevention
• · BLA submitted to FDA for etentamig in relapsed/refractory multiple myeloma

30-10-2026

Stryker reported Q3 2026 net sales of $6,520M, up 7.6% YoY from $6,057M, with nine-month sales of $19,129M (+6.6%). However, quarterly profitability deteriorated: operating income fell 8.9% to $1,034M and net earnings declined 12.3% to $753M as gross margin compressed and goodwill/other impairments jumped to $293M from $73M, driving diluted EPS down 11.7% to $1.96. Nine-month net earnings still rose 15.7% to $2,774M and diluted EPS grew 16.0% to $7.19, while the company repurchased $1,000M of stock and paid down $1,000M of long-term debt.

• · Gross margin compressed to 65.2% in Q3 2026 from 63.6% in Q3 2025 on a gross profit basis ($4,248M vs $3,852M)
• · Selling, general and administrative expenses rose 13.1% YoY to $2,313M in Q3 2026
• · Research, development and engineering expenses increased 5.6% YoY to $433M
• · Effective tax rate rose to 24.5% in Q3 2026 from 16.5% in Q3 2025
• · Ortho Tech was the fastest-growing orthopaedics line, up 15.8% YoY to $754M in Q3
• · Spinal Implants revenue collapsed to $4M in Q3 2026 from $6M, and nine-month fell to $9M from $177M following business sale
• · Hips declined 0.9% YoY to $453M while Knees grew only 1.1% (flat)
• · Nine-month operating cash flow rose to $3,303M from $2,901M
• · Cash and equivalents fell to $3,271M from $4,011M at year-end 2025
• · Total current liabilities fell to $6,500M from $7,794M at December 31, 2025
• · Contract liabilities declined to $960M from $1,024M at beginning of period
• · Nine-month acquisitions totaled $481M versus $4,950M in the prior-year period